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Breast cancer is the second leading cause of cancer mortality among women. 
Mammography and tumor biopsy followed by histopathological analysis are the current 
methods to diagnose breast cancer. Mammography does not detect all breast tumor 
subtypes; especially those arise in younger women or women with dense breast tissue, 
and are more aggressive. There is an urgent need to find circulating prognostic 
molecules and liquid biopsy methods for breast cancer diagnosis and reducing the 
mortality rate. In this study, we systematically evaluated metabolites and proteins in 
blood to develop a pipeline to identify potential circulating biomarkers for breast cancer 
risk. Our aim is to identify a group of molecules to be used in the design of portable and 
low-cost biomarker detection devices. We obtained plasma samples from women who 
are cancer free (healthy) and women who were cancer free at the time of blood 
collection but developed breast cancer later (susceptible). We extracted potential 
prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics 
data using statistical and discriminative power analyses. We pre-processed the data to 
ensure the quality of subsequent analyses, and used two main feature selection methods to 
determine the importance of each molecule. After further feature elimination based on 
pairwise dependencies, we measured the performance of logistic regression classifier 
on the remaining molecules and compared their biological relevance. We identified six 
signatures that predicted breast cancer risk with different specificity and selectivity. The 
best performing signature had 13 factors. We validated the difference in level of one of 
biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These 




































































identification of breast cancer risk and hence decreased mortality. Our findings provide 
the knowledge basis needed to proceed in this direction. 
Keywords: Liquid biopsy, Breast cancer risk, circulating biomarker, Machine 





































































Breast cancer is the second leading cause of death among adult women. 
According to World Health Organization, there is a sharp rise in overall number of 
breast cancer incidences world-wide due to changes in life style, reproductive factors 
and increased life expectancy [1]. Fifty eight percent of all breast cancer-related deaths 
occur in middle- and low-income countries. While survival rates for breast cancer are 
around 80% in developed countries, this rate decreases to 60% in middle-income and to 
40% in low-income countries due to lack of early detection programs leading to 
diagnoses in late stages, where 80% of these tumors are incurable [2, 3].  In the middle- 
and low-income countries, mammography and other expensive and technologically 
complicated methods are unattainable due to high costs and shortage of trained 
personnel. [4, 5] Moreover, mammograms are more likely to detect ER-positive breast 
cancer [6] and are not recommended for younger women. In addition, diagnosis at an 
earlier stage using conventional procedures is not prognostic for all race groups, for 
example, the probability of an African-American woman with small-sized tumors 
presenting with metastasis is higher than that of a Caucasian women.[7] Thus, there is 
a critical need for affordable, portable and accurate means of detecting breast cancer 
risk before the tumors arise. Development of such technologies has the potential to 
expedite the solution for the growing health problem to prevent increasing death and 
disability among women especially in low- and middle-income countries. 
Currently, a handful of biomarkers are used in the clinic for breast cancer 
diagnosis. These biomarkers are proteins overexpressed in certain subtypes of breast 




































































cancer biomarkers demonstrated clinical utility, including Estrogen Receptor alpha 
(ER ), P e e e Rece  (P R),[8] and human epidermal growth factor receptor 2 
(HER2) to predict effectiveness of systemic therapy and the Oncotype DX-21 gene 
score to predict benefits of chemotherapy. [9-11] Studies evaluating other predictive 
biomarkers are in progress for Breast Cancer susceptibility genes (BRCA1 and BRCA2) 
circulating tumor cells (CTCs), HER2 (+), TOP2A (in subjects with HER2 
overexpression) and HER2 (when is negative in tumors but is positive in the CTCs).[12] 
Circulating tumor DNA (ctDNA) is increasingly used in the clinic, particularly for 
advanced solid tumors.[13-15]  However, clinical utility and validity of ctDNA assays in 
early stage cancers is not as clear.[15] Further, we still lack reliable biomarkers to 
detect breast cancer risk before the tumors arise. Lack of such biomarkers hinders 
establishment of reliable screening or prevention programs.  
To address this critical need, we systematically evaluated metabolites and 
proteins in plasma to identify potential biomarkers for breast cancer risk that can be 
utilized to develop minimally invasive, affordable, portable, and accurate screening 
devices. In this study, our focus is on liquid biopsy samples from plasma that have the 
potential to provide simple and minimally invasive information for diagnostic decisions. 
We developed an efficient pipeline to analyze liquid biopsy samples, to detect blood 
biomarkers and to identify the risk for breast cancer before tumors arise. This pipeline 
paves the way towards developing the aforementioned screening devices to be used in 
the field by basic level healthcare workers in low-resource environments. 
Methods 




































































All studies were approved by the Indiana University Institutional Review Board 
(IRB protocol number 1011003097). All research was carried out in compliance with the 
Helsinki Declaration. Donors provided broad written consent for the use of their 
specimens in research. The written consent document informed the donor that the 
donated specimens and medical data would be used for the general purpose of helping 
to determine how breast cancer develops. It was explained in the written consent that 
the exact laboratory experiments were unknown at the time of donation, and that 
proposals for use of the specimens would be reviewed and approved by a panel of 
independent researchers before specimens and/or data were released for research 
purposes. Hematoxylin and eosin stained sections of the FFPE tissue of the identified 
donors were reviewed by pathologist to confirm the absence of histological 
abnormalities. In order to exclude or control confounding variables such as age, racial 
and ethnic background and menopausal status the subjects in the two cohorts, 
susceptible and healthy controls, were matched by selection of the comparison group 
(healthy controls) with respect to the distribution of the above mentioned confounders in 
susceptible group. 
Plasma preparation 
Blood was drawn into the Plasma Separator tube (Vacutainer Venous Blood 
Collection Tubes: SST* Plasma Separation Tube, Fisher Scientific cat. #0268396) and 
gently mixed by inverting the tube 5 times. Forty-five minutes (±10 min.) after the blood 
had been drawn, the Plasma Separator Tube was placed into a minicentrifuge 




































































temperature. A repeater pipet was used to aliquot 600ul of the plasma into each of five 
cryogenic vials. Samples were stored at -80°C until use. 
OLINK Protein biomarker and whole metabolite profiling assays  
All the samples from human studies were handled and analyzed in accordance 
with UIUC IRB protocol #06741 and as previously described [16]. 10 µl of plasma 
samples from Komen Tissue Bank were submitted to OLINK biosciences for cancer and 
inflammation biomarker analysis. 50 µl of plasma samples were submitted to the 
Metabolomics Center at UIUC. GC/MS whole metabolite profiling was performed to 
detect and quantify the metabolites by using gas chromatography-mass spectrometry 
(GC/MS) analysis. Metabolites were extracted from 50 µl of plasma according to Agilent 
Inc. application notes. The hentriacontanoic acid was added to each sample as the 
internal standard prior to derivatization. Metabolite profiles were acquired using an 
Agilent GC/MS system (Agilent 7890 gas chromatograph, an Agilent 5975 MSD, and an 
HP 7683B autosampler). The spectra of all chromatogram peaks were evaluated using 
the AMDIS 2.71 and a custom-built database with 460 unique metabolites. All known 
artificial peaks were identified and removed prior to data analysis. To allow the 
comparison between samples, all data were normalized to the internal standard in each 
chromatogram.   
Statistical Analysis  
Preprocessing of Measurements 
We normalized all i d d a  plasma data in each dataset with respect to the 




































































data acquisition. More specifically, we performed the following procedure separately for 
both datasets. For each molecule in a dataset, we subtracted the mean measurement of 
that ec e  ea  d d a   a  d d a  measurements and divided this 
d e e ce b  e a da d de a   a  ec e  ea e e   ea  
individuals. Thus, we converted each single measurement to a z-score which describes 
e de a   a  ea e e   e ea   ea  d d a ,  e   e 
standard deviation among healthy individuals. As the final step, we merged two 
datasets, which were normalized with respect to their own healthy individuals, and 
obtained a dataset with 49 susceptible and 47 healthy individuals. 
Molecule Ranking, Elimination and Performance Assessment 
A two-stage procedure is applied to identify the molecule sets with high 
discriminative power between the healthy and the susceptible groups. The first stage 
involves ranking all molecules with respect to their individual discriminative powers 
(importance ranking). The second stage involves molecule elimination (selection) based 
on their interdependencies. 
To independently assess each of 181 molecules, we used two different methods. 
In the first method, we applied S de  -test to test the null hypothesis that the 
measurements in the two groups come from the same distribution. All molecules were 
ranked based on the corresponding p-values to get a short-list of the top-ranking 20 
molecules with the lowest p-values, discarding the others from further processing. In the 
second method, we applied the random forest algorithm to assess the discriminative 
power of each of the 181 molecules individually by using the mean decrease impurity 





































































trees in the forest. This time, all molecules were ranked based on their Gini importance 
values to get the top-ranking 20 molecules with the highest importance values. No further 
threshold was applied to these top-ranking molecules at this stage for both methods, as 
the low-ranking molecules in these lists may potentially have significant marginal 
contribution to a subset of molecules when used together. 
To generate an optimum subset of the top 20 molecules identified by S de  -
test or random forest, we used the following iterative procedure. We a ed a e ec ed 
ec e   (S-list) with the top- a  ec e a d a  e ec ed ec e   
(U-list) with the remaining 19 ranked molecules. We iteratively assessed the individual 
molecules in the U-list with respect to the molecules set represented by the S-list, and 
added the ones that have a positive contribution to the S-list while discarding the others. 
Three different approaches are applied to assess whether a molecule has a positive 
contribution to the S-list: (i) Manual selection: Logistic Regression (LR) classifiers, to 
identify healthy and susceptible groups, are trained and tested iteratively by using the selected 
molecules (S-list) and the top-ranking unselected molecule (U-list) as the features. The classifier 
performance is assessed using the  selected molecules  AUC (Area Under Curve) of ROC 
(Receiver Operator Characteristic) curves. After each iteration, if the AUC is increased, the top-
ranking unselected molecule is added to the S-list, otherwise discarded. The iterations stop 
when the U-list is exhausted. (ii) Paired t-test: The inter-molecule dependencies, as 
measured by the paired t-test, is used to select the molecules from the U-list to be added 
to the S-list. We first computed the paired t-test p-values for each pair of molecules among 
the aforementioned top-ranking 20 molecules with the null hypothesis being that both 




































































molecules from the U-list that have p-value larger than 0.05 when tested with anyone of 
the molecules from the S-list and moved the unselected molecule from U-list to S-list with 
the lowest maximum p-value (<0.05) when tested with the selected molecules. The 
iterations stop when the U-list is exhausted. (iii) Correlation Analysis: The second approach 
described above is repeated by replacing the null hypothesis testing with the correlation analysis 
as measured by the Pea  c e a  c e c e  ( CC). We ed 0.5 a  e CC 
threshold. 
Finally, we performed LR classification (4-fold cross-validation with 500 iterations) 
using the top-ranking N molecules in each list, where N runs from one to the length of the 
corresponding list. Of note, use of LR for performance assessment of classification at this 
last step is distinct from the earlier use of LR for manual selection of the molecules. 
SCF/KITLG quantification using enzyme-linked immunosorbent assay 
(ELISA) 
Plasma samples from both groups were collected, and stored at -80°C until the 
time of assay. We used an enzyme-linked immunosorbent assay (ELISA) kit for 
SCF/KITLG (Sigma, catalogue no. RAB0330). Samples were diluted two fold per 
suggestion from the manufacturer. For SCF/KITLG the antibody, concentrate was 
diluted 100 fold with 1X Diluent Buffer. To prepare the HRP-Streptavidin Concentrate 
the vial was spin and diluted 400 times with 1X Diluent Buffer. A 50ng/ml stock solution 
was used to make the standard curve: 2000 pg/ml, 666.7pg/ml, 222.2 pg/ml, 
74.07pg/ml, 24.69pg/ml, 8.23 pg/ml and 2.74pg/ml for SCF/KITLG.  The Human 
SCF/KITLG antibody-pre coated ELISA wells were filled with 100µl of either serially 




































































shaking at room temperature, 100µl of 1x SCF/KITLG Biotinylated Detection Antibody 
were added to the wells. After one-hour incubation with shaking at room temperature, 
the solution was discarded and the wells were washed four times using 300µL wash 
buffer solution. Final wash was aspirated and plates were inverted to remove any 
remaining was buffer. Then, 100µl of Prepared HRP Streptavidin solution was added to 
each well, and incubated for 45 minutes at room temperature with gentle shaking. The 
solution was discarded and washed four times as described previously. 100µl of ELISA 
colorimetric TMB reagent was added to each well and incubated for 30 minutes at room 
temperature in the dark. After this, 50µl of Stop solution was added to each well. 
Immediately after color development, the OD values were measured at 450nm using 
Cytation 5 Cell Imaging Multi Mode- Reader (Biotek) and SCF/KITLG concentrations 
were calculated from specific calibration curves prepared with known standard 
solutions. Diluent buffer served as blank and the OD of these wells was subtracted from 
the values.  
Results 
Identification of circulating factor signatures for future breast cancer risk 
assessment 
Because we wanted to identify circulating factors that might indicate future breast 
cancer risk, we utilized plasma samples from a cohort of healthy controls (Healthy) and 
individuals who were clinically healthy at the time of plasma collection but later had a 
diagnosis of breast cancer (Susceptible). We analyzed plasma samples using whole 
metabolite profiling and OLINK biomarker analysis for a panel of inflammation and 




































































36 healthy and the other with 10 susceptible and 11 healthy individuals, which were 
collected at different times. In the first set, 22 out of 39 susceptible and 23 out of 36 
healthy individuals were postmenopausal status and remaining ones were 
premenopausal. In the second dataset, 7 out of 10 susceptible and 8 out of 11 healthy 
individuals were postmenopausal status and remaining ones were premenopausal. 
Average time to diagnosis was 3.7 years after samples donation (median is 4 years). 
Data from two datasets were pre-processed separately because they were acquired at 
different times, and were expected to have a variation due to external factors.  Plasma 
levels of 295 different molecules for the first dataset and 339 different molecules for the 
second dataset were detected for the individuals. Some molecules had missing values 
(were not detected by metabolomics or OLINK approach) for some individuals and 
further, some molecules were not measured for both datasets. All these molecules were 
excluded from the analysis. Therefore, we analyzed 181 different molecules, consisting 
of metabolites and proteins, which have plasma level values for every subject in both 
datasets. 
In order to generate an inclusive list of features that would best discriminate 
between healthy and susceptible individuals, we took a stepwise approach where we 
first screened all molecules that contribute to increased classifier performance (LR) and 
then iteratively eliminate the redundant ones for both top-ranking molecule lists obtained 
by either of the initial molecule selection methods. We initially selected two different 
  20 ec e  (   181 ec e )  e S de  -test and random 
forest (600 trees) methods to rank all 181 molecules with respect to their (healthy vs 




































































d e e  ea e e ec  e d , S de  -test and random forest, contain 10 
common molecules, highly concentrated in the upper halves of the lists. For example, 4 
out of 5 top ranking molecules are common in both datasets. To assess the pairwise 
dependencies among the most discriminative 20 molecules and further reduce the 
number of features in our lists we used the paired t-test (Table 1-S de  -test-, Table 
2-random forest-) or pairwise correlation analysis (Table 3-S de  -test-, Table 4-
random forest-). To ensure that all molecules that might positively contribute to classifier 
performance are included in the signature we performed logistic regression. Finally, to 
eliminate redundant molecules, we utilized paired t-test p-values (p>0.05) and/or 
correlation coefficients (pCC>0.5) to discard one of the molecules in that pair. Our 
approach resulted in six molecule signatures (Table 5-S de  -test-, Table 6-random 
forest-). 
Assessment of classification performances of molecule signatures using 
machine-learning approach 
In order to test the classification performance of each molecule signature, we 
performed LR classification using the molecules indicated in Table 5 and Table 6. Of 
note, use of LR for performance assessment of classification at the last step is distinct 
from the earlier use of LR for manual selection of the molecules. Our top 20 feature list 
e e a ed b  S de  -test contained MMP-10, MCP-3, SCF/KITLG, TRAIL, EN-
RAGE, MAD HOMOLOG 5 (SMAD5), CXL17, HK11, FGF-BP1, XPNPEP2, C15:0 
(Pentadecanoic acid), PPY, FGF-5, FGF-21, ESM-1, FASLG, CD160, TNFB, CTSV and 
ADA (Figure 1A). Unsupervised clustering of the data using this list of molecules 




































































classified with susceptible individuals and only one individual was classified together 
with healthy individuals (Figure 1A). This list without any further feature elimination 
achieved AUC value of 0.83 (Figure 1B).  Reduction of feature number to 13 using 
manual selection increased AUC value to 0.85±0.04 (Figure 1C). Further reduction of 
feature using correlation analysis (Figure 1D; AUC=0.78±0.04) or paired t-test (Figure 
1E; AUC=0.69±0.03). On the other hand, AUC values achieved by molecule signatures 
using Random Forest had lower performance (Figure 2). This list contained XPNPEP2, 
phosphoric acid, FGF-BP1, MAD HOMOLOG 5, ESM-1, SCF/KITLG, TRAIL, PD-L1, 
FLT3L, 4E-BP1, MCP-1, PPY, FGF-5, FASLG, MMP-10, EPHA2, CD27, CXCL1, HK14 
and TLR3 (Figure 2A). Unsupervised clustering of the data using this list of molecules 
was less successful in separating healthy and susceptible individuals, 10 of susceptible 
individuals were classified with healthy individuals (Figure 2A). Using all 20 factors 
achieved AUC of 0.80±0.05 (Figure 2B). Reducing the molecule number to 10 using 
manual selection (Figure 2C, AUC=0.80±0.04), to 11 using correlation analysis (Figure 
2D, AUC=0.76±0.05) or to two using paired t-test (Figure 2E, AUC=0.67±0.04) did not 
improve the AUC values. T  , a  ea e e ec   S de  -test followed 
by manual selection using LR gave us the best performing list of 13 circulating 
molecules from plasma for differentiating between healthy and susceptible individuals.  
Biological Relevance of Biomarkers 
Our best performing list contained SCF/KITLG, MMP-10, MAD HOMOLOG5, 
CXL17, MCP-3, FGF05, FASLG, CD160, TNFB, ESM-1, FGF-21, XPNPEP2 and CTSV 
(Figure 3A). In order to increase our understanding of molecules in the best performing 




































































healthy and susceptible individuals accurately (Figure 3A). To delve further into 
direction of change in the plasma levels of identified molecules we compared level of 
individual molecules in healthy vs. susceptible individuals. Six of the 13 molecules, 
including SCF/KITLG, MAD HOMOLOG 5, FASLG, MMP-10, XPNPEP2 and CXL17 
were statistically significantly different between the two groups (Figure 3B). Since our 
aim was to identify the molecules that have marginal but significant contribution to the 
classification task when used together with other molecules, even if they have weak 
discriminative power on their own, we still included these molecules with poor t-test 
performance individually, p-value>0.05, or low random forest importance in the final 
lists. We were particularly interested in SCF/KITLG as this molecule was the top 
molecule identified in both feature selection methods (Table 5 and 6). Overall, 
SCF/KITLG levels were lower in individuals with increased breast cancer risk (Figure 
3C). We also validated our finding from OLINK analysis using another independent 
method, ELISA analysis, and verified that level of this protein is lower in susceptible 
individuals (Figure 3B).  
Discussion 
In this study, we developed a pipeline to identify plasma biomarkers of breast 
cancer risk using a combination of classical statistics methods and machine learning 
approaches, and independently validated one of the identified biomarkers, SCF/KITLG. 
By iterative feature selection, elimination and performance testing we generated a 
molecular signature of plasma biomarkers that can discriminate between healthy and 




































































in this signature had weak discriminative power on their own, yet they contributed 
significantly to the discriminative power of the signature.  
A biomarker is a biomolecule, such as DNA, RNA, proteins, hormones and 
chemical modifications that can be measured to describe that an abnormal or a normal 
process is taking place within the organism. [12]  A cancer biomarker can arise due to 
changes in the DNA (mutations), rearrangements, deletions (missing copies), or 
amplifications. Biomarkers might affect various hallmarks of cancer including cell cycle, 
cell death, or immunological properties of the tumor and indicate the risk of developing 
cancer, its progression and response to therapy. [8, 9, 12]  
Previously, Kazarian et al, studied pre-diagnostic samples from the UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Serum samples were 
taken from 239 women who were diagnosed with invasive ductal carcinoma in breast 
(IDC), months to years after sample donation [17]. These patients were post-
menopausal women with ages ranging from 50 to 74, who were healthy cases at the 
moment of recruitment but that later developed breast cancer. Hence, this group studied 
the ability of several serum markers to detect breast cancer cases before these patients 
were diagnosed. They studied CA 15-3, RANTES/CCL5, OPN, PAI-1, SLP1, HSP90A, 
IGFBP3, APOC1 and PAPPA. They concluded that only 3 out of the 9 serum markers, 
(CA 15-3, PAI1 and HSP90A) were potential prognostic biomarkers[17].  Those 
analyses were performed using a limited panel of proteins. However, in our analysis, we 
characterized more than 300 proteins and metabolites in plasma and used a final list of 




































































One potential marker of interest we identified is SCF/KITLG protein. KITLG 
protein is expressed in 53% of breast cancer cell lines[18]. SCF/KITLG was shown to 
have a proliferative role in BCK4 cells, and when it is reduced, it decreased estrogen-
induced proliferation[19]. We identified lower level of this biomarker in plasma from 
women with breast cancer risk. Since at the time of the blood draw the women did not 
have tumors it is not possible for us to infer level of this protein in the tumor. Whether 
SCF plays a role in the induction of breast tumors or lower plasma levels of this protein 
contributes to the tumor biology needs to be determined. 
Several of the molecules in our signature were also implicated in cancer biology. 
For example, MAD HOMOLOG5/SMAD5 plays a role in breast cancer cell stemness, 
and resistance to chemotherapy. [20, 21] FGF-5, FASLG, CTSV and ESM-1 expression 
is associated with lower survival and worst outcomes. [22-27] MMP-10 affects 
angiogenesis and apoptosis [28, 29]; XPNPEP2 is overexpressed in cervical cancer 
patients and increases motility and invasiveness of tumors. [30] FGF-21, TNFB 
contributes to metastatic potential of breast cancer cells. [31, 32] CXL17 [33], MCP-
3[34] and CD160 [35] play a role in recruitment of immune cells. TNFB/LTA 
polymorphisms increased the cancer risk in various populations. [36, 37] All these 
studies focused on the tumors or patients that already have cancers. The impact of 
proteins in our signature on breast cancer risk and initiation remains to be established. 
Direction of differences in the plasma levels of these proteins between healthy and 
susceptible individuals might be different from what is reported in already established 





































































More recently, liquid biopsy methods supported with machine-learning 
approaches have been used for the detection of different cancer types.[15, 38, 39] For 
example, Cohen et al. recently demonstrated the capability of detecting eight different 
cancer types including breast cancer using circulating tumor DNA (ctDNA) and protein 
biomarkers [40]. They reported remarkable sensitivity values >95% for ovarian and liver 
cancers. However, the reported sensitivity for breast cancer is rather low at 33%. The 
novelty of our study is identifying circulating molecules that are associated with future 
cancer risk and developing a pipeline to utilize these markers in generation of 
biosensors based on our previous work to detect breast cancer risk. [41]  
We used a combination of various statistical analysis methods to identify 
biomarkers. Although, Student  t-test and/or random forest give some information 
about the ability of a biomarker to discriminate between healthy and susceptible 
patients, it alone is not sufficient. To identify the biomarkers with high classification 
performance, we applied logistic regression. Area under curve (AUC) of receiver 
operating characteristic (ROC) curves resulting from the classification operations on 
these biomarkers are commonly used as an indicator for the discriminative capacity of a 
single molecule or a set of molecules. Previously, logistic regression was performed on 
predictors consisting of serum levels of several molecules, but authors did not report 
any confidence interval for that AUC value and did not split the data into training and 
test tests.[42] I  a e  d , a  ed S de  -test and its non-parametric 
equivalence (Mann-Whitney U-test) to find potential biomarkers, but the lower bound of 
their reported confidence intervals was dramatically low, suggesting that those 




































































Several other studies have also used these methods to identify potential biomarkers but 
have not utilized a train-set split for their datasets.[17, 44-46] Training (Model building) 
and testing on the same dataset is not an ideal practice in machine learning as the 
model is likely to over-fit to the data. This approach results in artificially high predictive 
rates, in other words, low generalizability, which refers to poor applicability of the model 
to unseen data. The cross-validation that we employed in this study is a common 
approach to circumvent the problem of overfitting.  
Conclusion 
We identified biomarkers of breast cancer risk using metabolomics and protein 
profiling in plasma samples from healthy and susceptible individuals. Future studies are 
required to validate these markers in bigger data sets, to determine their role in breast 
tumorigenesis, develop liquid biopsy/biosensor-based approaches and move this 
information to clinic for early identification of breast cancer risk. In addition, further 
molecular studies in cell lines and animal models are required to show conclusively 
whether or not each or a combination of these markers can be utilized as indicators of 
breast cancer risk without having observable effects on breast cancer cells or can have 
other roles at the earlier stages of carcinogenesis. Overall, our analysis offers novel 
plasma biomarkers for further validation and functional characterization.  
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Table and Figure legends 
Table 1. The p-values of the paired t-test analysis for each pair of molecules 
among the top 20 molecules ranked by a  e S de  -test to all 181 
molecules. The paired t-test assesses the pairwise dependencies of the most 
discriminative 20 molecules. Pairs with p>0.05 show strong dependency within that pair. 
Table 2. The p-values of the paired t-test analysis for each pair of molecules 
among the top 20 molecules ranked by applying the random forest to all 181 molecules. 
The paired t-test assesses the pairwise dependencies of the most discriminative 20 
molecules. Pairs with p>0.05 show strong dependency within that pair. 
Table 3. Pea  c e a  c e c e  be ee  eac  a   20  
important molecules ranked by their Student  t-test p-values. Pairs with pCC>0.5 show 
strong dependency within that pair.  
Table 4. Pea  c e a  c e c e  be ee  eac  a   20  
important molecules ranked by their importance calculated by random forest. Pairs with 
pCC>0.5 show strong dependency within that pair.  
Table 5. Ranking of molecules identified by initial S de  -test for each 
consequent feature elimination method. T e S de  - e  c   e  
ranking most discriminative 20 molecules among 181 ec e .  T e Ma a  




































































selected from these 20 top molecules by applying the iterative molecule elimination 
procedures using manual selection by LR based on classification performance, paired t-
test and correlation analysis, respectively, as described in Statistical Analysis. 
Table 6. Ranking of molecules identified by initial random forest method for each 
consequent feature elimination method. T e Ra d  F e  c   e  
ranking most discriminat e 20 ec e  a  181 ec e .  T e Ma a  
Selection by LR , Pa ed - e  a d C e a  A a  c   e ec e  
selected from these 20 top molecules by applying the iterative molecule elimination 
procedures using manual selection by LR based on classification performance, paired t-
test and correlation analysis, respectively, as described in Statistical Analysis. 
Figure 1. Identification and performance assessment of circulating factor 
signatures for future breast cancer risk asses men  ing S den  -test as 
initial feature selection method (A) Le e    20 ec e  de ed b  S de  
t-test in 47 healthy (red) and 49 susceptible (green) individuals using OLINK analysis. Z-
Scores were not log transformed or centered. Unsupervised hierarchical clustering was 
performed using Cluster 3 software for Z-scores of molecule concentrations with 
uncentered correlation as similarity metric and average linkage as clustering method.  
Data are visualized using Java Tree view software. In the lower panel, each column 
represents an individual and each row represents a molecule, with elevated levels in 
red, reduced levels in blue, and mean control levels in white. Bar indicates the coloring 
for Z-scores of molecule concentrations. (B) LR classification performances (AUC 
values) using the top-ranking N (1-20) molecules, ranked by their p-values in Table 5, 




































































of the best performing (the highest AUC value) molecule set. (C) LR classification 
performances (AUC values) using the top-ranking N (1-13) molecules selected manually 
by considering the LR classification performance given in Figure 1B and the ROC 
curves of every AUC value where the bold black line indicates ROC curve of the best 
performing (the highest AUC value) molecule set. (D) LR classification performances 
(AUC values) using the top-ranking molecules selected from the list of 20 molecules, 
a ed b  S de  -test in Table 5, by iterative elimination using pair-wise Pearson 
correlation coefficients of features in Table 3 (|pCC|=0.5 is the significance threshold). 
The ROC curves of every AUC value where the bold black line indicates ROC curve of 
the best performing (the highest AUC value) molecule set. (E) LR classification 
performances (AUC values) using the top-ranking N (1-2) molecules selected from the 
  20 ec e , a ed b  S de  -test in Table 5, by iterative elimination using 
paired t-test p-values of features in Table 1 (p=0.05 is the significance threshold). The 
ROC curves of every AUC value where the bold black line indicates ROC curve of the 
best performing (the highest AUC value) molecule set. 
Figure 2. Identification and performance assessment of circulating factor 
signatures for future breast cancer risk assessment using random forest as initial 
feature selection method (A) Levels of top 20 molecules identified by random forest 
method in 47 healthy (red) and 49 susceptible (green) individuals using OLINK analysis. 
Z-Scores were not log transformed or centered. Unsupervised hierarchical clustering 
was performed using Cluster 3 software for Z-scores of molecule concentrations with 
uncentered correlation as similarity metric and average linkage as clustering method.    




































































represents an individual and each row represents a molecule, with elevated levels in 
red, reduced levels in blue, and mean control levels in white. Bar indicates the coloring 
for Z-scores of molecule concentrations. (B) LR classification performances (AUC 
values) using the top-ranking N (1-20) molecules, ranked by their feature importance 
values (computed by random forest) in Table 6, and the ROC curves of every AUC 
value where the bold black line indicates ROC curve of the best performing (the highest 
AUC value) molecule set. (C) LR classification performances (AUC values) using the 
top-ranking molecules selected manually by considering the LR classification 
performance given in Figure 2B and the ROC curves of every AUC value where the 
bold black line indicates ROC curve of the best performing (the highest AUC value) 
molecule set. (D) LR classification performances (AUC values) using the top-ranking N 
(1-11) molecules selected from the list of 20 molecules, ranked by random forest in 
Table 6, by iterative elimination using pair-wise Pearson correlation coefficients of 
features in Table 4 (|pCC|=0.5 is the significance threshold). The ROC curves of every 
AUC value where the bold black line indicates ROC curve of the best performing (the 
highest AUC value) molecule set. (E) LR classification performances (AUC values) 
using the top-ranking N (1-2) molecules selected from the list of 20 molecules, ranked 
by random forest in Table 6, by iterative elimination using paired t-test p-values of 
features in Table 2 (p=0.05 is the significance threshold). The ROC curves of every 
AUC value where the bold black line indicates ROC curve of the best performing (the 
highest AUC value) molecule set.  
Figure 3. A. Validation of biomarker identification. (A) Levels of 13 molecules 




































































susceptible (green) individuals using OLINK analysis. Z-Scores were not log 
transformed or centered. Unsupervised hierarchical clustering was performed using 
Cluster 3 software for Z-scores of molecule concentrations with uncentered correlation 
as similarity metric and average linkage as clustering method.  Data are visualized 
using Java Tree view software. In the lower panel, each column represents an individual 
and each row represents a molecule, with elevated levels in red, reduced levels in blue, 
and mean control levels in white. Bar indicates the coloring for Z-scores of molecule 
concentrations. (B) Changes in the levels of 12 of 13 signature molecules in 47 healthy 
and 49 susceptible individuals. Anderson-Darling and Kolmogorov-Smirnov tests for 
normal  a  ed. I  e da a e  d d  a  e a  e , -parametric Mann-
Whitney test was used to assess if level of a molecule is statistically significantly 
different in plasma from healthy vs. susceptible individuals (molecules with *). 
Otherwise, unpaired t-test was used to assess if level of a molecule is statistically 
significantly different in plasma from healthy vs. susceptible individuals. All data points 
are plotted. P-values are indicted on the graphs. (C) Level of SCF/KITLG in 47 healthy 
and 49 susceptible individuals. Anderson-Darling and Kolmogorov-Smirnov tests for 
normality was used. Non-parametric Mann-Whitney test was used to assess if level of a 
molecule is statistically significantly different in plasma from healthy vs. susceptible 
individuals. All data points are plotted (as histogram on the left side and as box-
whiskers graph on right side). P-values are indicted on the graph. (D) Results from 3C 
are independently validated using ELISA assay using all the samples. Level of identified 
biomarkers in human plasma samples were compared using unpaired t-test. P-value is 


































































Table 1 SCF MAD HOMOLOG 5FGF- FASLG MMP-10 PPY
SCF 0 0.6963 0.0004 0.0006 0.3286 0.0017
MAD HOMOLOG 5 0.6963 0 0.0013 0.0014 0.6643 0.0038
FGF-5 0.0004 0.0013 0 0.6618 0.002 0.7183
FASLG 0.0006 0.0014 0.6618 0 0.0018 0.9554
MMP-10 0.3286 0.6643 0.002 0.0018 0 0.0033
PPY 0.0017 0.0038 0.7183 0.9554 0.0033 0
XPNPEP2 0.361 0.5633 0.0018 0.0015 0.9115 0.0054
FGF-21 0.003 0.0026 0.6703 0.9738 0.0006 0.9356
CXL17 0.2659 0.4489 0.0017 0.0034 0.8086 0.0018
MCP-3 0.189 0.2985 0.0027 0.002 0.542 0.0055
ESM-1 0.0003 0.0006 0.6315 0.9137 0.0073 0.8852
HK11 0.1552 0.3257 0.0064 0.0015 0.5825 0.0063
TRAIL 0.1309 0.5298 0.0033 0.0039 0.8731 0.0096
FGF-BP1 0.1303 0.2913 0.01 0.0112 0.5308 0.0166
EN-RAGE 0.1191 0.354 0.0027 0.005 0.6119 0.0124
C15:0 0.1324 0.2454 0.0091 0.0067 0.417 0.0109
TNFB 0.0029 0.008 0.4087 0.6151 0.0071 0.6315
CTSV 0.0045 0.0062 0.4174 0.548 0.0154 0.6427
ADA 0.001 0.0083 0.6858 0.9595 0.0169 0.93
CD160 0.0015 0.007 0.4709 0.6497 0.0086 0.6801
Table 1
XPNPEP2 FGF-21 CXL17 MCP-3 ESM-1 HK11 TRAIL FGF-BP1
0.361 0.003 0.2659 0.189 0.0003 0.1552 0.1309 0.1303
0.5633 0.0026 0.4489 0.2985 0.0006 0.3257 0.5298 0.2913
0.0018 0.6703 0.0017 0.0027 0.6315 0.0064 0.0033 0.01
0.0015 0.9738 0.0034 0.002 0.9137 0.0015 0.0039 0.0112
0.9115 0.0006 0.8086 0.542 0.0073 0.5825 0.8731 0.5308
0.0054 0.9356 0.0018 0.0055 0.8852 0.0063 0.0096 0.0166
0 0.0034 0.9172 0.66 0.0125 0.6878 0.9708 0.6209
0.0034 0 0.0014 0.0029 0.9489 0.006 0.0063 0.013
0.9172 0.0014 0 0.7384 0.0038 0.7438 0.9536 0.6714
0.66 0.0029 0.7384 0 0.0089 0.9712 0.7017 0.9032
0.0125 0.9489 0.0038 0.0089 0 0.0032 0.0061 0.013
0.6878 0.006 0.7438 0.9712 0.0032 0 0.7392 0.8734
0.9708 0.0063 0.9536 0.7017 0.0061 0.7392 0 0.6469
0.6209 0.013 0.6714 0.9032 0.013 0.8734 0.6469 0
0.6971 0.0134 0.7648 0.9911 0.0112 0.9815 0.6816 0.9125
0.4563 0.0096 0.5413 0.788 0.0289 0.7421 0.5747 0.8767
0.0108 0.7003 0.0172 0.0183 0.7453 0.0202 0.0092 0.0416
0.0055 0.6644 0.026 0.017 0.7257 0.0234 0.0274 0.0442
0.0188 0.9805 0.019 0.0211 0.9715 0.037 0.0071 0.0429
0.0214 0.7499 0.0126 0.0241 0.7768 0.0087 0.0078 0.0441
EN-RAGE C15:0 TNFB CTSV ADA CD160
0.1191 0.1324 0.0029 0.0045 0.001 0.0015
0.354 0.2454 0.008 0.0062 0.0083 0.007
0.0027 0.0091 0.4087 0.4174 0.6858 0.4709
0.005 0.0067 0.6151 0.548 0.9595 0.6497
0.6119 0.417 0.0071 0.0154 0.0169 0.0086
0.0124 0.0109 0.6315 0.6427 0.93 0.6801
0.6971 0.4563 0.0108 0.0055 0.0188 0.0214
0.0134 0.0096 0.7003 0.6644 0.9805 0.7499
0.7648 0.5413 0.0172 0.026 0.019 0.0126
0.9911 0.788 0.0183 0.017 0.0211 0.0241
0.0112 0.0289 0.7453 0.7257 0.9715 0.7768
0.9815 0.7421 0.0202 0.0234 0.037 0.0087
0.6816 0.5747 0.0092 0.0274 0.0071 0.0078
0.9125 0.8767 0.0416 0.0442 0.0429 0.0441
0 0.8043 0.0374 0.025 0.0115 0.0327
0.8043 0 0.0409 0.0464 0.0725 0.0502
0.0374 0.0409 0 0.969 0.7488 0.9447
0.025 0.0464 0.969 0 0.7132 0.9266
0.0115 0.0725 0.7488 0.7132 0 0.8146



















































































































































































































































































































































































































































































Table 3 SCF MAD HOMOLOG 5FGF- FASLG MMP-10 PPY XPNPEP2
SCF 1 0.136 0.129 0.076 0.318 -0.088 0.03
MAD HOMOLOG 5 0.136 1 0.057 0.064 -0.048 -0.119 0.148
FGF-5 0.129 0.057 1 0.21 0.047 0.15 0.123
FASLG 0.076 0.064 0.21 1 0.079 0.169 0.179
MMP-10 0.318 -0.048 0.047 0.079 1 -0.002 0.156
PPY -0.088 -0.119 0.15 0.169 -0.002 1 -0.047
XPNPEP2 0.03 0.148 0.123 0.179 0.156 -0.047 1
FGF-21 -0.189 0.021 0.104 0.192 0.32 0.085 0.11
CXL17 0.215 0.323 0.151 0.037 0.323 0.199 0.168
MCP-3 0.03 0.217 0.116 0.165 0.281 0.012 0.15
ESM-1 0.265 0.305 0.067 0.149 -0.087 -0.006 -0.169
HK11 0.261 0.208 -0.048 0.246 0.264 0.022 0.188
TRAIL 0.66 0.244 0.113 0.127 0.294 -0.065 -0.03
FGF-BP1 0.228 0.118 -0.073 -0.068 0.076 -0.147 0.004
EN-RAGE 0.415 0.132 0.233 0.154 0.143 -0.034 0.118
C15:0 0 0.017 -0.027 0.075 0.097 0.003 0.227
TNFB 0.073 0.012 0.184 0.285 0.159 0.089 0.138
CTSV -0.024 0.083 0.049 0.384 -0.042 -0.175 0.281
ADA 0.312 0.089 0.219 0.12 0.043 0.035 0.083
CD160 0.223 0.082 0.161 0.446 0.158 0.173 -0.018
Table 3
FGF-21 CXL17 MCP-3 ESM-1 HK11 TRAIL FGF-BP1 EN-RAGE
-0.189 0.215 0.03 0.265 0.261 0.66 0.228 0.415
0.021 0.323 0.217 0.305 0.208 0.244 0.118 0.132
0.104 0.151 0.116 0.067 -0.048 0.113 -0.073 0.233
0.192 0.037 0.165 0.149 0.246 0.127 -0.068 0.154
0.32 0.323 0.281 -0.087 0.264 0.294 0.076 0.143
0.085 0.199 0.012 -0.006 0.022 -0.065 -0.147 -0.034
0.11 0.168 0.15 -0.169 0.188 -0.03 0.004 0.118
1 0.276 0.2 -0.124 0.092 0.101 0.003 0.005
0.276 1 0.129 0.164 0.32 0.198 0.092 0.141
0.2 0.129 1 0.02 0.068 0.214 0.112 0.319
-0.124 0.164 0.02 1 0.269 0.16 0.072 0.117
0.092 0.32 0.068 0.269 1 0.176 0.187 0.047
0.101 0.198 0.214 0.16 0.176 1 0.134 0.435
0.003 0.092 0.112 0.072 0.187 0.134 1 -0.055
0.005 0.141 0.319 0.117 0.047 0.435 -0.055 1
0.103 0.131 -0.112 -0.187 0.13 -0.066 0.008 -0.136
0.016 0.042 0.11 0.075 0.112 0.28 -0.017 0.019
0.038 -0.096 0.133 -0.026 0.071 -0.009 -0.034 0.165
0.065 0.119 0.202 0.233 0.007 0.379 0.062 0.41
0.097 0.17 0.079 0.299 0.352 0.333 0.006 0.107
C15:0 TNFB CTSV ADA CD160
0 0.073 -0.024 0.312 0.223
0.017 0.012 0.083 0.089 0.082
-0.027 0.184 0.049 0.219 0.161
0.075 0.285 0.384 0.12 0.446
0.097 0.159 -0.042 0.043 0.158
0.003 0.089 -0.175 0.035 0.173
0.227 0.138 0.281 0.083 -0.018
0.103 0.016 0.038 0.065 0.097
0.131 0.042 -0.096 0.119 0.17
-0.112 0.11 0.133 0.202 0.079
-0.187 0.075 -0.026 0.233 0.299
0.13 0.112 0.071 0.007 0.352
-0.066 0.28 -0.009 0.379 0.333
0.008 -0.017 -0.034 0.062 0.006
-0.136 0.019 0.165 0.41 0.107
1 0.035 -0.012 -0.162 -0.001
0.035 1 0.048 0.204 0.275
-0.012 0.048 1 0.25 -0.087
-0.162 0.204 0.25 1 0.054
-0.001 0.275 -0.087 0.054 1
Table 4 SCF MAD HOMOLOG 5PPY FASLG FGF-5 CXCL1 MMP-10
SCF 1 0.136 -0.088 0.076 0.129 0.227 0.318
MAD HOMOLOG 5 0.136 1 -0.119 0.064 0.057 -0.029 -0.048
PPY -0.088 -0.119 1 0.169 0.15 -0.038 -0.002
FASLG 0.076 0.064 0.169 1 0.21 0.19 0.079
FGF-5 0.129 0.057 0.15 0.21 1 0.044 0.047
CXCL1 0.227 -0.029 -0.038 0.19 0.044 1 0.195
MMP-10 0.318 -0.048 -0.002 0.079 0.047 0.195 1
XPNPEP2 0.03 0.148 -0.047 0.179 0.123 -0.094 0.156
ESM-1 0.265 0.305 -0.006 0.149 0.067 0.01 -0.087
PHOSPHORIC ACID 0.05 0.067 -0.016 -0.011 0.09 -0.158 -0.111
PD-L1 0.363 0.061 0.235 0.229 0.28 0.317 0.499
EPHA2 0.382 0.271 0.148 0.347 0.218 0.197 0.352
FLT3L 0.395 0.105 0.102 0.098 0.253 0.263 0.348
4E-BP1 0.297 0.231 -0.014 0.107 0.18 0.202 0.101
TRAIL 0.66 0.244 -0.065 0.127 0.113 0.439 0.294
MCP-1 0.277 0.152 0.184 0.262 0.319 0.402 0.369
TLR3 -0.011 0.15 -0.017 0.149 0.178 0.126 0.047
CD27 0.131 0.133 -0.011 0.159 0.081 0.235 0.343
FGF-BP1 0.228 0.118 -0.147 -0.068 -0.073 0.066 0.076
HK14 0.159 0.157 -0.072 0.246 -0.068 0.319 0.209
Table 4
XPNPEP2 ESM-1 PHOSPHORIC ACIDPD-L1 EPHA2 FLT3L 4E-BP1 TRAIL
0.03 0.265 0.05 0.363 0.382 0.395 0.297 0.66
0.148 0.305 0.067 0.061 0.271 0.105 0.231 0.244
-0.047 -0.006 -0.016 0.235 0.148 0.102 -0.014 -0.065
0.179 0.149 -0.011 0.229 0.347 0.098 0.107 0.127
0.123 0.067 0.09 0.28 0.218 0.253 0.18 0.113
-0.094 0.01 -0.158 0.317 0.197 0.263 0.202 0.439
0.156 -0.087 -0.111 0.499 0.352 0.348 0.101 0.294
1 -0.169 0.063 0.119 0.151 0.145 0.2 -0.03
-0.169 1 -0.015 0.166 0.489 0.117 0.179 0.16
0.063 -0.015 1 -0.046 0.073 -0.066 0.082 -0.058
0.119 0.166 -0.046 1 0.525 0.635 0.316 0.484
0.151 0.489 0.073 0.525 1 0.358 0.165 0.431
0.145 0.117 -0.066 0.635 0.358 1 0.27 0.534
0.2 0.179 0.082 0.316 0.165 0.27 1 0.422
-0.03 0.16 -0.058 0.484 0.431 0.534 0.422 1
0.071 0.136 -0.015 0.519 0.368 0.507 0.579 0.466
0.02 0.029 -0.138 0.083 0.17 0.128 0.036 0.01
0.048 0.23 -0.166 0.452 0.642 0.159 0.054 0.217
0.004 0.072 -0.009 -0.053 0.064 0.043 0.067 0.134
0.121 0.196 -0.196 0.296 0.195 0.075 0.12 0.13
MCP-1 TLR3 CD27 FGF-BP1 HK14
0.277 -0.011 0.131 0.228 0.159
0.152 0.15 0.133 0.118 0.157
0.184 -0.017 -0.011 -0.147 -0.072
0.262 0.149 0.159 -0.068 0.246
0.319 0.178 0.081 -0.073 -0.068
0.402 0.126 0.235 0.066 0.319
0.369 0.047 0.343 0.076 0.209
0.071 0.02 0.048 0.004 0.121
0.136 0.029 0.23 0.072 0.196
-0.015 -0.138 -0.166 -0.009 -0.196
0.519 0.083 0.452 -0.053 0.296
0.368 0.17 0.642 0.064 0.195
0.507 0.128 0.159 0.043 0.075
0.579 0.036 0.054 0.067 0.12
0.466 0.01 0.217 0.134 0.13
1 0.042 0.155 0.03 0.121
0.042 1 0.138 -0.125 0.083
0.155 0.138 1 0.05 0.316
0.03 -0.125 0.05 1 0.239
0.121 0.083 0.316 0.239 1
Table 5
Table 5
Rank Student t-TestManual SelectionCorrelation AnalysisPaired t-Test
1 SCF SCF SCF SCF
2 MAD HOMOLOG 5MAD HOMOLOG 5MAD HOMOLOG 5FGF-5
3 FGF-5 FGF-5 FGF-5
4 FASLG FASLG FASLG
5 MMP-10 MMP-10 PPY
6 PPY XPNPEP2 XPNPEP2
7 XPNPEP2 FGF-21 FGF-21
8 FGF-21 CXL17 MCP-3
9 CXL17 MCP-3 FGF-BP1















Rank Random ForestManual SelectionCorrelation AnalysisPaired t-Test
1 SCF SCF SCF SCF
2 MAD HOMOLOG 5MAD HOMOLOG 5MAD HOMOLOG 5PPY
3 PPY PPY PPY
4 FASLG FASLG FASLG
5 FGF-5 FGF-5 FGF-5
6 CXCL1 MMP-10 CXCL1
7 MMP-10 XPNPEP2 XPNPEP2
8 XPNPEP2 ESM-1 PHOSPHORIC ACID
9 ESM-1 FLT3L TLR3
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